95333-13-4

Usage

Uses

Used in Pharmaceutical Industry:
4-Benzofurancarboxaldehyde (9CI) is used as a key intermediate in the synthesis of various pharmaceuticals. Its aromatic aldehyde structure allows for the creation of a wide range of medicinal compounds, contributing to the development of new drugs and therapies.
Used in Agrochemical Industry:
In the agrochemical sector, 4-Benzofurancarboxaldehyde (9CI) serves as a crucial component in the production of various agrochemicals. Its chemical properties make it suitable for the development of pesticides, herbicides, and other agricultural chemicals that are essential for crop protection and yield enhancement.
Used in Organic Compounds Synthesis:
4-Benzofurancarboxaldehyde (9CI) is utilized as a building block in the synthesis of diverse organic compounds. Its reactivity and structural features facilitate the creation of complex organic molecules for various applications in research and industry.
Used in Flavor and Fragrance Industry:
4-Benzofurancarboxaldehyde (9CI) is used as a flavor and fragrance ingredient in the food and cosmetic industry. Its strong and sweet odor makes it an important component in the formulation of perfumes, colognes, and food flavorings, enhancing the sensory experience of these products.
Used in Cosmetic Industry:
In the cosmetic industry, 4-Benzofurancarboxaldehyde (9CI) is employed for its aromatic properties, contributing to the scent profiles of various cosmetic products. Its use in this sector highlights its versatility and the broad range of applications it offers across different industries.

Upstream product

• 68-12-2 N,N-dimethyl-formamide 
• 204452-94-8 2-(3-bromophenoxy)acetaldehyde diethyl acetal 

Downstream Products

• 173470-67-2 4-hydroxymethylbenzofurane 
• 1027186-29-3 3-Benzofuran-4-yl-2-(4-methoxy-benzoyl)-4-nitro-butyric acid ethyl ester 
• 1026632-01-8 4-Benzofuran-4-yl-2-(4-methoxy-phenyl)-4,5-dihydro-3H-pyrrole-3-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of Formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and ischemia reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of Formula (IA).

THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).

Potent and selective non-benzodioxole-containing endothelin-A receptor antagonists

The benzodioxole ((methylenedioxy)benzene) group is present in a number of endothelin (ET) receptor antagonists thus far reported. As part of our own endothelin antagonist program we have developed (2R*,3R*,4S*)-1-(N,N- dibutylacetamido)-4-(1,3-benzodioxol-5-yl)-2-(4-methoxyphenyl)pyrrolidine-3- carboxylic acid (A-127722). This is a potent antagonist, binding to the ET(A) and ET(B) receptor subtypes with affinities (IC50) of 0.4 and 520 nM, respectively, and also contains the aforementioned benzodioxole. While this compound was seemingly optimized at its N-terminus, no effort had been directed toward understanding the contributions to binding affinity or receptor subtype selectivity conferred by the benzodioxole. Substitution by 1- or 2-naphthyl yielded weak antagonists. Oxygenated benzenes, such as p- anisyl, were potent compounds with IC50s in the low-nanomolar range. Simple deletion of either of the two oxygen atoms (dihydrobenzofurans) yielded extremely potent agents, possessing subnanomolar affinity for the ET(A) receptor. Additionally, the compounds showed enhanced selectivity, binding to the ET(B) receptor subtype in the micromolar range. This paper describes the development of this novel class of compounds.